> top > docs > PubMed:24929024 > annotations

PubMed:24929024 JSONTXT

Annnotations TAB JSON ListView MergeView

sentences

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-118 Sentence denotes Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: its potential use in the treatment of bladder cancers.
TextSentencer_T2 119-263 Sentence denotes Urothelial carcinoma of the bladder is the most frequent tumor of the urinary tract and represents the fifth cause of death by cancer worldwide.
TextSentencer_T3 264-390 Sentence denotes The current first line chemotherapy is a combination of cisplatin and gemcitabine with median survival not exceeding 15months.
TextSentencer_T4 391-631 Sentence denotes Vinflunine is the only drug approved by EMEA as second-line treatment and few progresses have been made for the past 20years to increase the survival of metastatic patients, especially those who are not eligible for cisplatin-based regimen.
TextSentencer_T5 632-822 Sentence denotes The recent studies characterizing the genetic background of urothelial cancers of the bladder, revealed chromosomal alterations that are not seen at the same level in other types of cancers.
TextSentencer_T6 823-982 Sentence denotes This is especially the case for mutations of genes involved in the PI3K/AKT/mTOR signaling pathway that occupies a major place in the etiology of these tumors.
TextSentencer_T7 983-1209 Sentence denotes Here, we describe the mutations leading to constitutive activation of the PI3K/AKT/mTOR pathway and discuss the potential use of the different classes of PI3K/AKT/mTOR inhibitors in the treatment of urothelial bladder cancers.
TextSentencer_T8 1210-1459 Sentence denotes Despite the recent pivotal study evidencing specific mutations of TSC1 in bladder cancer patients responding to everolimus and the encouraging results obtained with other derivatives than rapalogs, few clinical trials are ongoing in bladder cancers.
TextSentencer_T9 1460-1738 Sentence denotes Because of the genetic complexity of these tumors, the cross-talks of the PI3K/AKT/mTOR pathway with other pathways, and the small number of eligible patients, it will be of utmost importance to carefully choose the drugs or drug combinations to be further tested in the clinic.
T1 0-118 Sentence denotes Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: its potential use in the treatment of bladder cancers.
T2 119-263 Sentence denotes Urothelial carcinoma of the bladder is the most frequent tumor of the urinary tract and represents the fifth cause of death by cancer worldwide.
T3 264-390 Sentence denotes The current first line chemotherapy is a combination of cisplatin and gemcitabine with median survival not exceeding 15months.
T4 391-631 Sentence denotes Vinflunine is the only drug approved by EMEA as second-line treatment and few progresses have been made for the past 20years to increase the survival of metastatic patients, especially those who are not eligible for cisplatin-based regimen.
T5 632-822 Sentence denotes The recent studies characterizing the genetic background of urothelial cancers of the bladder, revealed chromosomal alterations that are not seen at the same level in other types of cancers.
T6 823-982 Sentence denotes This is especially the case for mutations of genes involved in the PI3K/AKT/mTOR signaling pathway that occupies a major place in the etiology of these tumors.
T7 983-1209 Sentence denotes Here, we describe the mutations leading to constitutive activation of the PI3K/AKT/mTOR pathway and discuss the potential use of the different classes of PI3K/AKT/mTOR inhibitors in the treatment of urothelial bladder cancers.
T8 1210-1459 Sentence denotes Despite the recent pivotal study evidencing specific mutations of TSC1 in bladder cancer patients responding to everolimus and the encouraging results obtained with other derivatives than rapalogs, few clinical trials are ongoing in bladder cancers.
T9 1460-1738 Sentence denotes Because of the genetic complexity of these tumors, the cross-talks of the PI3K/AKT/mTOR pathway with other pathways, and the small number of eligible patients, it will be of utmost importance to carefully choose the drugs or drug combinations to be further tested in the clinic.

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 130-154 HP_0002862 denotes carcinoma of the bladder
T2 176-202 HP_0010786 denotes tumor of the urinary tract
T3 176-181 HP_0002664 denotes tumor
T4 246-252 HP_0002664 denotes cancer
T5 703-725 HP_0009725 denotes cancers of the bladder
T6 703-710 HP_0002664 denotes cancers
T7 814-821 HP_0002664 denotes cancers
T8 975-981 HP_0002664 denotes tumors
T9 1193-1208 HP_0009725 denotes bladder cancers
T10 1201-1208 HP_0002664 denotes cancers
T11 1284-1298 HP_0009725 denotes bladder cancer
T12 1292-1298 HP_0002664 denotes cancer
T13 1443-1458 HP_0009725 denotes bladder cancers
T14 1451-1458 HP_0002664 denotes cancers
T15 1503-1509 HP_0002664 denotes tumors

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
24929024-0#41#45#gene5290 41-45 gene5290 denotes PI3K
24929024-0#41#45#gene5291 41-45 gene5291 denotes PI3K
24929024-0#41#45#gene5293 41-45 gene5293 denotes PI3K
24929024-0#41#45#gene5294 41-45 gene5294 denotes PI3K
24929024-0#46#49#gene207 46-49 gene207 denotes AKT
24929024-0#102#117#diseaseC0005684 102-117 diseaseC0005684 denotes bladder cancers
24929024-0#102#117#diseaseC0005684 102-117 diseaseC0005684 denotes bladder cancers
24929024-7#66#70#gene7248 1276-1280 gene7248 denotes TSC1
24929024-7#66#70#gene7248 1276-1280 gene7248 denotes TSC1
24929024-7#74#88#diseaseC0005684 1284-1298 diseaseC0005684 denotes bladder cancer
24929024-7#74#88#diseaseC0005695 1284-1298 diseaseC0005695 denotes bladder cancer
24929024-7#74#88#diseaseC0699885 1284-1298 diseaseC0699885 denotes bladder cancer
24929024-7#233#248#diseaseC0005684 1443-1458 diseaseC0005684 denotes bladder cancers
41#45#gene5290102#117#diseaseC0005684 24929024-0#41#45#gene5290 24929024-0#102#117#diseaseC0005684 associated_with PI3K,bladder cancers
41#45#gene5290102#117#diseaseC0005684 24929024-0#41#45#gene5290 24929024-0#102#117#diseaseC0005684 associated_with PI3K,bladder cancers
41#45#gene5291102#117#diseaseC0005684 24929024-0#41#45#gene5291 24929024-0#102#117#diseaseC0005684 associated_with PI3K,bladder cancers
41#45#gene5291102#117#diseaseC0005684 24929024-0#41#45#gene5291 24929024-0#102#117#diseaseC0005684 associated_with PI3K,bladder cancers
41#45#gene5293102#117#diseaseC0005684 24929024-0#41#45#gene5293 24929024-0#102#117#diseaseC0005684 associated_with PI3K,bladder cancers
41#45#gene5293102#117#diseaseC0005684 24929024-0#41#45#gene5293 24929024-0#102#117#diseaseC0005684 associated_with PI3K,bladder cancers
41#45#gene5294102#117#diseaseC0005684 24929024-0#41#45#gene5294 24929024-0#102#117#diseaseC0005684 associated_with PI3K,bladder cancers
41#45#gene5294102#117#diseaseC0005684 24929024-0#41#45#gene5294 24929024-0#102#117#diseaseC0005684 associated_with PI3K,bladder cancers
46#49#gene207102#117#diseaseC0005684 24929024-0#46#49#gene207 24929024-0#102#117#diseaseC0005684 associated_with AKT,bladder cancers
46#49#gene207102#117#diseaseC0005684 24929024-0#46#49#gene207 24929024-0#102#117#diseaseC0005684 associated_with AKT,bladder cancers
66#70#gene724874#88#diseaseC0005684 24929024-7#66#70#gene7248 24929024-7#74#88#diseaseC0005684 associated_with TSC1,bladder cancer
66#70#gene724874#88#diseaseC0005695 24929024-7#66#70#gene7248 24929024-7#74#88#diseaseC0005695 associated_with TSC1,bladder cancer
66#70#gene724874#88#diseaseC0699885 24929024-7#66#70#gene7248 24929024-7#74#88#diseaseC0699885 associated_with TSC1,bladder cancer
66#70#gene7248233#248#diseaseC0005684 24929024-7#66#70#gene7248 24929024-7#233#248#diseaseC0005684 associated_with TSC1,bladder cancers
66#70#gene724874#88#diseaseC0005684 24929024-7#66#70#gene7248 24929024-7#74#88#diseaseC0005684 associated_with TSC1,bladder cancer
66#70#gene724874#88#diseaseC0005695 24929024-7#66#70#gene7248 24929024-7#74#88#diseaseC0005695 associated_with TSC1,bladder cancer
66#70#gene724874#88#diseaseC0699885 24929024-7#66#70#gene7248 24929024-7#74#88#diseaseC0699885 associated_with TSC1,bladder cancer
66#70#gene7248233#248#diseaseC0005684 24929024-7#66#70#gene7248 24929024-7#233#248#diseaseC0005684 associated_with TSC1,bladder cancers

DisGeNet-2017-sample

Id Subject Object Predicate Lexical cue
T1200 41-45 gene:5290 denotes PI3K
T1201 102-117 disease:C0005684 denotes bladder cancers
T1202 1276-1280 gene:7248 denotes TSC1
T1203 1284-1298 disease:C0005684 denotes bladder cancer
R1 T1200 T1201 associated_with PI3K,bladder cancers
R2 T1200 T1201 associated_with PI3K,bladder cancers
R3 T1200 T1201 associated_with PI3K,bladder cancers
R4 T1200 T1201 associated_with PI3K,bladder cancers
R5 T1202 T1203 associated_with TSC1,bladder cancer
R6 T1202 T1203 associated_with TSC1,bladder cancer
R7 T1202 T1203 associated_with TSC1,bladder cancer